Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants

References

• Lacey CJN, Lowndes CM, Shah KV. Chapter 4: burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine. 2006;24(Supplement 3):1–9. doi:10.1016/j.vaccine.2006.06.015.
   PubMedGoogle Scholar
• de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2020;8(2):e180–190. doi:10.1016/S2214-109X(19)30488-7.
   PubMed Web of Science ®Google Scholar
• Bruni L, Albero G, Serrano B. ICO/IARC information centre on HPV and cancer (HPV information centre). Human papillomavirus and related diseases in India. Summary Report; 2021 Oct 14 [accessed 2022 Jan 14]. https://hpvcentre.net/statistics/reports/IND.pdf.
   Google Scholar
• Arbyn A, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, and Bray F. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8(2):e191–e203. doi:10.1016/S2214-109X(19)30482-6.
   PubMed Web of Science ®Google Scholar
• Luxembourg A, Moeller E. 9-Valent human papillomavirus vaccine: a review of the clinical development program. Expert Rev Vaccines. 2017;16(11):1119–1139. doi:10.1080/14760584.2017.1383158.
   PubMed Web of Science ®Google Scholar
• de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664–670. doi:10.1002/ijc.30716.
   PubMed Web of Science ®Google Scholar
• Garland SM, Steben M, Sings HL, James M, Lu S, Railkar R, Barr E, Haupt RM, and Joura EA. Natural history of genital warts: Analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis. 2009;199(6):805–814. doi:10.1086/597071.
   PubMed Web of Science ®Google Scholar
• Barr E, Gause CK, Bautista OM, Railkar RA, Lupinacci LC, Insinga RP, Sings HL, and Haupt RM. Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women. Am J Obstet Gynecol. 2008;198(3):261.e1–261.e11. doi:10.1016/j.ajog.2007.09.001.
   PubMed Web of Science ®Google Scholar
• Majewski S, Bosch FX, Dillner J, Iversen O-E, Kjaer SK, Muñoz N, Olsson S-E, Paavonen J, Sigurdsson K, Bryan J et al. The impact of a quadrivalent human papillomavirus (types 6, 11, 16, 18) virus-like particle vaccine in European women aged 16 to 24. J Eur Acad Dermatol Venereol. 2009;23(10):1147–1155. doi:10.1111/j.1468-3083.2009.03266.x.
   PubMed Web of Science ®Google Scholar
• Perez G, Lazcano-Ponce E, Hernandez-Avila M, García PJ, Muñoz N, Villa LL, Bryan J, Taddeo FJ, Lu S, Esser MT et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women. Int J Cancer. 2008;122(6):1311–1318. doi:10.1002/ijc.23260.
   PubMed Web of Science ®Google Scholar
• Tay EH, Garland S, Tang G, Nolan T, Huang L-M, Orloski L, Lu S, Barr E. Clinical trial experience with prophylactic HPV 6/11/16/18 VLP vaccine in young women from the Asia-Pacific region. Int J Gynaecol Obstet. 2008;102(3):275–283. doi:10.1016/j.ijgo.2008.03.021.
   PubMed Web of Science ®Google Scholar
• Giuliano AR, Lazcano-Ponce E, Villa L, Nolan T, Marchant C, Radley D, Golm G, McCarroll K, Yu J, Esser MT et al. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine. J Infect Dis. 2007;196(8):1153–1162. doi:10.1086/521679.
   PubMed Web of Science ®Google Scholar
• Huh WK, Joura EA, Giuliano AR, Iversen O-E, de Andrade RP, Ault KA, Bartholomew D, Cestero RM, Fedrizzi EN, Hirschberg AL et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial. Lancet. 2017;390(10108):2143–2159. doi:10.1016/S0140-6736(17)31821-4.
   PubMed Web of Science ®Google Scholar
• Petersen LK, Restrepo J, Moreira ED, Jr., Iversen O-E, Pitisuttithum P, Van Damme P, Joura EA, Olsson S-E, Ferris D, Block S et al. Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine – a combined analysis of five phase III clinical trials. Papillomavirus Res. 2017;3:105–115. doi:10.1016/j.pvr.2017.03.002.
   PubMed Web of Science ®Google Scholar
• Mugo N, Ansah NA, Marino D, Saah A, and Garner EIO. Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa. Hum Vaccin Immunother. 2015;11(6):1323–1330. doi:10.1080/21645515.2015.1008877.
   PubMed Web of Science ®Google Scholar
• Van Damme P, Olsson SE, Block S, Castellsague X, Gray GE, Herrera T, Huang L-M, Kim DS, Pitisuttithum P, Chen J et al. Immunogenicity and safety of a 9-valent HPV vaccine. Pediatrics. 2015;136(1):e28–39. doi:10.1542/peds.2014-3745.
   PubMed Web of Science ®Google Scholar
• Luxembourg A, Moreira ED, Jr., Samakoses R, Kim K-H, Sun X, Maansson R, Moeller E, Christiano S, and Chen J. Phase III, randomized controlled trial in girls 9-15 years old to evaluate lot consistency of a novel nine-valent human papillomavirus L1 virus-like particle vaccine. Hum Vaccin Immunother. 2015;11(6):1306–1312. doi:10.1080/21645515.2015.1009819.
   PubMed Web of Science ®Google Scholar
• International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH: E 6 (R2): guideline for good clinical practice - step 5. [ accessed 2022 July 1]. https://www.ema.europa.eu/en/ich-e6-r2-good-clinical-practice.
   Google Scholar
• Dias D, Van Doren J, Schlottmann S, Kelly S, Puchalski D, Ruiz W, Boerckel P, Kessler J, Antonello JM, Green T et al. Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin Diagn Lab Immunol. 2005;12(8):959–969. doi:10.1128/CDLI.12.8.959-969.2005.
   PubMedGoogle Scholar
• Opalka D, Lachman CE, MacMullen SA, Jansen KU, Smith JF, Chirmule N, Esser MT. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol. 2003;10(1):108–115. doi:10.1128/cdli.10.1.108-115.2003.
   PubMedGoogle Scholar
• Smith JF, Kowalski R, Esser MT, Brown MJ, Bryan JT. Evolution of type-specific immunoassays to evaluate the functional immune response to Gardasil: a vaccine for human papillomavirus types 16, 18, 6 and 11. Hum Vaccin. 2008;4(2):134–142. doi:10.4161/hv.4.2.5261.
   PubMed Web of Science ®Google Scholar
• Roberts C, Green T, Hess E, Matys K, Brown MJ, Haupt RM, Luxembourg A, Vuocolo S, Saah A, Antonello J. Development of a human papillomavirus competitive luminex immunoassay for 9 HPV types. Hum Vaccin Immunother. 2014;10(8):2168–2174. doi:10.4161/hv.29205.
   PubMed Web of Science ®Google Scholar
• The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915–1927. doi:10.1056/NEJMoa061741.
   PubMed Web of Science ®Google Scholar
• Olsson SE, Restrepo JA, Reina JC, Pitisuttithum P, Ulied A, Varman M, Van Damme P, Moreira ED, Jr., Ferris D, Block S et al. Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up. Papillomavirus Res. 2020;10:100203. doi:10.1016/j.pvr.2020.100203.
   PubMed Web of Science ®Google Scholar
• Ferris DG, Samakoses R, Block SL et al. 4-Valent human papillomavirus (4vhpv) vaccine in preadolescents and adolescents after 10 years. Pediatrics. 2017;140(6):e20163947. doi:10.1542/peds.2016-3947.
   PubMed Web of Science ®Google Scholar
• Kjaer SK, Nygård M, Sundström K, Dillner J, Tryggvadottir L, Munk C, Berger S, Enerly E, Hortlund M, Ágústsson ÁI et al. Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four Nordic countries. EClinicalMedicine. 2020;23:100401. doi:10.1016/j.eclinm.2020.100401.
   PubMedGoogle Scholar
• Kjaer S, Nygard M, Sundström K, Munk C, Berger S, Dzabic M, Fridrich KE, Waldstrøm M, Sørbye SW, Bautista O et al. Long-term effectiveness of the 9-valent human papillomavirus vaccine in Scandinavian women: interim analysis after 8 years of follow-up. Hum Vaccin Immunother. 2021;17(4):943–949. doi:10.1080/21645515.2020.1839292.
   PubMed Web of Science ®Google Scholar
• Goldstone SE, Giuliano AR, Palefsky JM, Lazcano-Ponce E, Penny ME, Cabello RE, Moreira ED, Jr., Baraldi E, Jessen H, Ferenczy A et al. Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis. 2022;22(3):413–425. doi:10.1016/S1473-3099(21)00327-3.
   PubMed Web of Science ®Google Scholar
• Brown D, Müller M, Sehr P, Pawlita M, Seitz H, Rubio I, Antonello J, Radley D, Roberts C, Saah A. Concordance assessment between a multiplexed competitive Luminex immunoassay, a multiplexed IgG Luminex immunoassay, and a pseudovirion-based neutralization assay for detection of human papillomavirus types 16 and 18. Vaccine. 2014;32(44):5880–5887. doi:10.1016/j.vaccine.2014.08.004.
   PubMed Web of Science ®Google Scholar
• Moreira ED, Jr., Block SL, Ferris D, Giuliano AR, Iversen O-E, Joura EA, Kosalaraksa P, Schilling A, Van Damme P, Bornstein J et al. Safety profile of the 9-valent HPV vaccine: A combined analysis of 7 Phase III clinical trials. Pediatrics. 2016;138(2):e20154387. doi:10.1542/peds.2015-4387.
   PubMed Web of Science ®Google Scholar
• Phillips A, Patel C, Pillsbury A, Brotherton J, Macartney K. Safety of human papillomavirus vaccines: an updated review. Drug Saf. 2018;41(4):329–346. doi:10.1007/s40264-017-0625-z.
   PubMed Web of Science ®Google Scholar
• Block SL, Brown DR, Chatterjee A, Gold MA, Sings HL, Meibohm A, Dana A, Haupt RM, Barr E, Tamms GM et al. Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) 1 virus-like particle vaccine. Pediatr Infect Dis J. 2010;29(2):95–101. doi:10.1097/INF.0b013e3181b77906.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Human papillomavirus vaccines: WHO position paper. Wkly Epidemiol Rec. 2017;92(19):241–268.
   PubMedGoogle Scholar
• Meites E, Kempe A, and Markowitz LE. Use of a 2-dose schedule for human papillomavirus vaccination - updated recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2016;65(49):1405–1408. doi:10.15585/mmwr.mm6549a5.
   PubMed Web of Science ®Google Scholar
• Kasi SG, Shivananda S, Marathe S, Chatterjee K, Agarwalla S, Dhir SK, Verma S, Shah AK, Srirampur S, Kalyani S et al. Indian Academy of Pediatrics (IAP) Advisory Committee on Vaccines and Immunization Practices (ACVIP): recommended immunization schedule (2020–21) and update on immunization for children aged 0 through 18 years. Indian Pediatr. 2021;58(1):44–54. doi:10.1007/s13312-021-2096-7.
   PubMed Web of Science ®Google Scholar
• Dobson SRM, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, Sauvageau C, Scheifele DW, Kollmann TR, Halperin SA et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA. 2013;309(17):1793–1802. doi:10.1001/jama.2013.1625.
   PubMed Web of Science ®Google Scholar
• Donken R, Dobson SRM, Marty KD, Cook D, Sauvageau C, Gilca V, Dionne M, McNeil S, Krajden M, Money D et al. Immunogenicity of 2 and 3 doses of the quadrivalent human papillomavirus vaccine up to 120 months postvaccination: follow-up of a randomized clinical trial. Clin Infect Dis. 2020;71(4):1022–1029. doi:10.1093/cid/ciz887.
   PubMed Web of Science ®Google Scholar
• Iversen OE, Miranda MJ, Ulied A, Soerdal T, Lazarus E, Chokephaibulkit K, Block SL, Skrivanek A, Nur Azurah AG, Fong SM et al. Immunogenicity of the 9-valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women. JAMA. 2016;316(22):2411–2421. doi:10.1001/jama.2016.17615.
   PubMed Web of Science ®Google Scholar
• Bornstein J, Roux S, Petersen LK, Huang L-M, Dobson SR, Pitisuttithum P, Diez-Domingo J, Schilling A, Ariffin H, Tytus R et al. Three-year follow-up of 2-dose versus 3-dose HPV vaccine. Pediatrics. 2021;147(1):e20194035. doi:10.1542/peds.2019-4035.
   PubMed Web of Science ®Google Scholar